COST-EFFECTIVENESS OF NIVOLUMAB plus IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDS

被引：0
|
作者：
Klijn, S. [1 ]
Van de Wetering, G. [1 ]
Malcolm, B. [2 ]
Dale, P. [2 ]
Pompen, M. [3 ]
Stevanovic, J. [3 ]
机构：
[1] Pharmerit Int, Rotterdam, Netherlands
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Utrecht, Netherlands
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.272
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN190
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLAND
    Oniangue-Ndza, C.
    Schneider, R.
    Malcolm, B.
    May, J.
    Gooden, K. M.
    Klijn, S.
    Cakar, E.
    VALUE IN HEALTH, 2019, 22 : S462 - S462
  • [22] COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALY
    Di Rienzo, P.
    Zarrelli, L.
    Mennini, F. S.
    Marcellusi, A.
    Bini, C.
    Malcolm, B.
    May, J.
    Gooden, K. M.
    Van de Wetering, G.
    van Carroll, Smith L. E.
    VALUE IN HEALTH, 2019, 22 : S469 - S469
  • [23] Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
    Wang, Ye
    Wang, Hao
    Yi, Manman
    Han, Zhou
    Li, Li
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] Cost-effectiveness of first-line treatments in metastatic renal cell carcinoma
    Benton, John Z.
    Klaassen, Zachary
    Wallis, Christopher J. D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (02) : 285 - 286
  • [25] Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer
    Hao, Xuezhi
    Shen, Aizong
    Wu, Bin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [26] Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma
    Wang, Siying
    Xie, Ouyang
    Wu, Meiyu
    Xiang, Heng
    Tan, Chongqing
    Wan, Xiaomin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, 25 (02) : 173 - 178
  • [27] COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN COLOMBIA
    Nunez, S. M.
    Godoy, J., I
    Cardona, A. F.
    Otero, J. M.
    Lujan, M.
    Lopera, D.
    Carranza, H.
    Spath, A.
    Gis, P. R.
    VALUE IN HEALTH, 2012, 15 (04) : A219 - A219
  • [28] Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma
    Zhu, Jiaxin
    Zhang, Tiantian
    Wan, Ning
    Liang, Zhuoru
    Li, Jiahao
    Chen, Xudong
    Liang, Wenhua
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (17) : 1237 - 1246
  • [29] Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (09) : 1507 - 1517
  • [30] First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
    Liu Yang
    Xiaobing Song
    Wanxian Zeng
    Zhiwei Zheng
    Wenqiang Lin
    Orphanet Journal of Rare Diseases, 18
12345